| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigen Presentation | 65 | 2025 | 228 | 15.120 |
Why?
|
| Histocompatibility Antigens Class I | 66 | 2025 | 132 | 13.240 |
Why?
|
| CD8-Positive T-Lymphocytes | 24 | 2025 | 651 | 5.590 |
Why?
|
| Antigen-Presenting Cells | 46 | 2020 | 176 | 3.390 |
Why?
|
| Cross-Priming | 8 | 2023 | 16 | 3.370 |
Why?
|
| Dendritic Cells | 19 | 2023 | 508 | 3.340 |
Why?
|
| T-Lymphocytes | 58 | 2016 | 969 | 3.080 |
Why?
|
| Lymphocyte Activation | 42 | 2017 | 742 | 2.980 |
Why?
|
| Cysteine Endopeptidases | 24 | 2016 | 91 | 2.510 |
Why?
|
| Histocompatibility Antigens Class II | 28 | 2016 | 179 | 2.450 |
Why?
|
| Antigens | 26 | 2023 | 146 | 2.250 |
Why?
|
| Mice | 134 | 2025 | 10343 | 2.200 |
Why?
|
| Animals | 166 | 2025 | 19768 | 2.190 |
Why?
|
| Aminopeptidases | 12 | 2020 | 28 | 2.090 |
Why?
|
| Endoplasmic Reticulum | 15 | 2020 | 169 | 2.070 |
Why?
|
| Peptides | 30 | 2020 | 551 | 2.000 |
Why?
|
| Proteasome Endopeptidase Complex | 27 | 2016 | 124 | 1.920 |
Why?
|
| Peptide Fragments | 15 | 2016 | 353 | 1.870 |
Why?
|
| Ovalbumin | 38 | 2009 | 113 | 1.860 |
Why?
|
| Multienzyme Complexes | 20 | 2004 | 77 | 1.850 |
Why?
|
| Mice, Inbred C57BL | 51 | 2025 | 3218 | 1.830 |
Why?
|
| Inflammation | 15 | 2024 | 1110 | 1.780 |
Why?
|
| Uric Acid | 6 | 2014 | 49 | 1.750 |
Why?
|
| T-Lymphocytes, Cytotoxic | 23 | 2010 | 169 | 1.720 |
Why?
|
| H-2 Antigens | 16 | 2010 | 61 | 1.650 |
Why?
|
| Interferon Regulatory Factor-2 | 2 | 2024 | 5 | 1.610 |
Why?
|
| Tumor Escape | 3 | 2023 | 16 | 1.590 |
Why?
|
| Mice, Knockout | 22 | 2025 | 1999 | 1.560 |
Why?
|
| beta 2-Microglobulin | 9 | 2025 | 47 | 1.540 |
Why?
|
| Interleukin-1 | 11 | 2012 | 155 | 1.500 |
Why?
|
| Neoplasms | 6 | 2025 | 1261 | 1.490 |
Why?
|
| Cell Death | 13 | 2014 | 272 | 1.470 |
Why?
|
| Lectins, C-Type | 3 | 2024 | 78 | 1.330 |
Why?
|
| Cathepsins | 4 | 2017 | 33 | 1.310 |
Why?
|
| Immunologic Surveillance | 4 | 2017 | 13 | 1.250 |
Why?
|
| Epitopes | 28 | 2011 | 296 | 1.240 |
Why?
|
| Immunotherapy | 2 | 2024 | 237 | 1.230 |
Why?
|
| Necrosis | 5 | 2019 | 140 | 1.200 |
Why?
|
| Antigens, Surface | 20 | 1999 | 192 | 1.200 |
Why?
|
| Adjuvants, Immunologic | 7 | 2006 | 228 | 1.110 |
Why?
|
| Phagosomes | 4 | 2019 | 44 | 1.110 |
Why?
|
| Interleukin-1beta | 4 | 2017 | 262 | 1.090 |
Why?
|
| Neoplasm Proteins | 10 | 2019 | 277 | 1.090 |
Why?
|
| Macrophages | 18 | 2020 | 1013 | 1.060 |
Why?
|
| Apoptosis | 7 | 2019 | 1040 | 1.030 |
Why?
|
| Major Histocompatibility Complex | 14 | 2023 | 87 | 1.020 |
Why?
|
| Thymus Gland | 10 | 2016 | 223 | 1.020 |
Why?
|
| Liver | 5 | 2019 | 789 | 0.980 |
Why?
|
| Cytotoxicity, Immunologic | 10 | 2009 | 144 | 0.970 |
Why?
|
| B-Lymphocytes | 22 | 2007 | 552 | 0.960 |
Why?
|
| Peritonitis | 4 | 2024 | 33 | 0.920 |
Why?
|
| Melanoma | 2 | 2024 | 335 | 0.910 |
Why?
|
| Inflammasomes | 4 | 2017 | 333 | 0.870 |
Why?
|
| Cell Line | 38 | 2012 | 2017 | 0.870 |
Why?
|
| Receptors, Cell Surface | 4 | 2019 | 439 | 0.860 |
Why?
|
| Membrane Proteins | 9 | 2022 | 847 | 0.860 |
Why?
|
| Antigens, Ly | 13 | 1998 | 40 | 0.840 |
Why?
|
| Immune System | 4 | 2010 | 129 | 0.830 |
Why?
|
| Signal Transduction | 13 | 2021 | 2891 | 0.800 |
Why?
|
| Cytosol | 10 | 2010 | 170 | 0.790 |
Why?
|
| Humans | 85 | 2025 | 60132 | 0.780 |
Why?
|
| Genes, MHC Class I | 4 | 2012 | 28 | 0.750 |
Why?
|
| Peptide Hydrolases | 6 | 2016 | 80 | 0.690 |
Why?
|
| RNA-Binding Proteins | 11 | 2011 | 388 | 0.680 |
Why?
|
| HeLa Cells | 15 | 2019 | 531 | 0.680 |
Why?
|
| Antigens, Viral | 7 | 2008 | 133 | 0.670 |
Why?
|
| Gout | 2 | 2012 | 53 | 0.650 |
Why?
|
| Immunodominant Epitopes | 5 | 2009 | 57 | 0.640 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 53 | 0.640 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2019 | 80 | 0.630 |
Why?
|
| Leucyl Aminopeptidase | 5 | 2007 | 5 | 0.630 |
Why?
|
| Biomarkers, Tumor | 14 | 2011 | 465 | 0.620 |
Why?
|
| Cells, Cultured | 19 | 2016 | 2101 | 0.620 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 4 | 2017 | 256 | 0.620 |
Why?
|
| Serine Endopeptidases | 3 | 2009 | 82 | 0.610 |
Why?
|
| Antibodies, Monoclonal | 17 | 2005 | 858 | 0.610 |
Why?
|
| Cathepsin B | 3 | 2017 | 13 | 0.610 |
Why?
|
| Amino Acid Sequence | 20 | 2010 | 1589 | 0.610 |
Why?
|
| Neutrophils | 3 | 2019 | 351 | 0.590 |
Why?
|
| CD40 Antigens | 3 | 2008 | 60 | 0.580 |
Why?
|
| Endopeptidases | 7 | 1999 | 68 | 0.570 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2014 | 41 | 0.570 |
Why?
|
| Graft Rejection | 2 | 2016 | 264 | 0.570 |
Why?
|
| Mice, Inbred BALB C | 26 | 2007 | 883 | 0.560 |
Why?
|
| Peptide Biosynthesis | 3 | 2012 | 10 | 0.550 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2013 | 207 | 0.550 |
Why?
|
| Ubiquitins | 10 | 1999 | 41 | 0.540 |
Why?
|
| Receptors, Interleukin-1 | 4 | 2013 | 64 | 0.540 |
Why?
|
| Phagocytosis | 6 | 2019 | 252 | 0.540 |
Why?
|
| Neutrophil Infiltration | 2 | 2014 | 61 | 0.540 |
Why?
|
| Hybridomas | 20 | 2001 | 65 | 0.530 |
Why?
|
| Clonal Selection, Antigen-Mediated | 1 | 2016 | 5 | 0.530 |
Why?
|
| Proteins | 11 | 2006 | 743 | 0.530 |
Why?
|
| Particulate Matter | 1 | 2017 | 59 | 0.530 |
Why?
|
| Histones | 1 | 2019 | 464 | 0.530 |
Why?
|
| Caspase 1 | 2 | 2017 | 110 | 0.530 |
Why?
|
| Cell Differentiation | 10 | 2016 | 1297 | 0.510 |
Why?
|
| Organ Transplantation | 1 | 2016 | 52 | 0.510 |
Why?
|
| Molecular Sequence Data | 20 | 2010 | 1983 | 0.500 |
Why?
|
| Fibroblasts | 4 | 2009 | 370 | 0.490 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 1384 | 0.490 |
Why?
|
| Inflammation Mediators | 3 | 2013 | 169 | 0.490 |
Why?
|
| Proteome | 2 | 2014 | 142 | 0.480 |
Why?
|
| Receptor, PAR-2 | 1 | 2014 | 3 | 0.470 |
Why?
|
| Thiazoles | 1 | 2014 | 46 | 0.470 |
Why?
|
| Lung Injury | 1 | 2014 | 32 | 0.470 |
Why?
|
| Immunologic Memory | 2 | 2008 | 284 | 0.460 |
Why?
|
| Protein Precursors | 5 | 2010 | 74 | 0.460 |
Why?
|
| Complement C3 | 1 | 2014 | 61 | 0.460 |
Why?
|
| Oligopeptides | 7 | 2007 | 130 | 0.450 |
Why?
|
| Adoptive Transfer | 4 | 2007 | 148 | 0.450 |
Why?
|
| Phosphatidylinositols | 6 | 1992 | 49 | 0.440 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 8 | 1991 | 106 | 0.440 |
Why?
|
| Minor Histocompatibility Antigens | 6 | 2020 | 34 | 0.440 |
Why?
|
| Adenosine Triphosphate | 3 | 2014 | 289 | 0.430 |
Why?
|
| Carrier Proteins | 4 | 2015 | 710 | 0.430 |
Why?
|
| Protein Processing, Post-Translational | 5 | 2012 | 256 | 0.420 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 201 | 0.420 |
Why?
|
| Interleukin-1alpha | 2 | 2010 | 25 | 0.410 |
Why?
|
| Cathepsin C | 1 | 2012 | 1 | 0.410 |
Why?
|
| Radiodermatitis | 1 | 2012 | 11 | 0.410 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 2 | 2009 | 10 | 0.400 |
Why?
|
| Receptors, Immunologic | 6 | 2004 | 177 | 0.400 |
Why?
|
| Haptens | 6 | 2007 | 13 | 0.400 |
Why?
|
| Interferon-gamma | 12 | 2002 | 551 | 0.390 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2012 | 9 | 0.390 |
Why?
|
| Dacarbazine | 1 | 2012 | 20 | 0.390 |
Why?
|
| Melanoma, Experimental | 3 | 2024 | 43 | 0.390 |
Why?
|
| Radiotherapy, Conformal | 1 | 2012 | 20 | 0.390 |
Why?
|
| Antibodies, Blocking | 3 | 2001 | 40 | 0.390 |
Why?
|
| Down-Regulation | 3 | 2019 | 306 | 0.390 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 225 | 0.380 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2008 | 109 | 0.380 |
Why?
|
| Transfection | 14 | 2009 | 676 | 0.380 |
Why?
|
| Immune System Diseases | 1 | 2011 | 17 | 0.380 |
Why?
|
| ATP-Binding Cassette Transporters | 5 | 2025 | 37 | 0.370 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 1991 | 280 | 0.370 |
Why?
|
| Antigens, Neoplasm | 4 | 2008 | 136 | 0.360 |
Why?
|
| Bacteria | 1 | 2013 | 278 | 0.360 |
Why?
|
| Protease Inhibitors | 6 | 2002 | 103 | 0.360 |
Why?
|
| Mice, Transgenic | 8 | 2012 | 1227 | 0.350 |
Why?
|
| Bone Marrow Cells | 5 | 2010 | 232 | 0.340 |
Why?
|
| Glioblastoma | 1 | 2012 | 156 | 0.340 |
Why?
|
| Macrophages, Peritoneal | 1 | 2010 | 73 | 0.340 |
Why?
|
| Lung | 1 | 2014 | 842 | 0.340 |
Why?
|
| Lymphocytic choriomeningitis virus | 3 | 2009 | 86 | 0.320 |
Why?
|
| Cell Membrane | 9 | 2005 | 492 | 0.310 |
Why?
|
| Vaccinia virus | 4 | 2004 | 73 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 11 | 2001 | 454 | 0.310 |
Why?
|
| Cricetinae | 6 | 2013 | 376 | 0.310 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 16 | 1991 | 24 | 0.310 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 306 | 0.300 |
Why?
|
| Mice, Inbred Strains | 10 | 2010 | 182 | 0.300 |
Why?
|
| Cells | 2 | 2010 | 30 | 0.300 |
Why?
|
| Allergy and Immunology | 1 | 2007 | 7 | 0.300 |
Why?
|
| Genes, MHC Class II | 10 | 1994 | 37 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 483 | 0.280 |
Why?
|
| HEK293 Cells | 2 | 2019 | 583 | 0.280 |
Why?
|
| CD40 Ligand | 2 | 2007 | 156 | 0.280 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 538 | 0.280 |
Why?
|
| Antigens, CD | 4 | 1998 | 344 | 0.280 |
Why?
|
| Spleen | 16 | 2006 | 486 | 0.270 |
Why?
|
| Hypertension | 1 | 2012 | 603 | 0.270 |
Why?
|
| Cell Communication | 1 | 2007 | 127 | 0.260 |
Why?
|
| Toll-Like Receptors | 4 | 2013 | 434 | 0.260 |
Why?
|
| Metalloendopeptidases | 2 | 2003 | 22 | 0.260 |
Why?
|
| Lymphocytes | 3 | 1994 | 194 | 0.260 |
Why?
|
| Immunization, Passive | 3 | 2005 | 100 | 0.260 |
Why?
|
| Peritoneum | 3 | 2014 | 25 | 0.260 |
Why?
|
| Endosomes | 3 | 2019 | 170 | 0.250 |
Why?
|
| G(M2) Ganglioside | 1 | 2005 | 9 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2007 | 621 | 0.250 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 21 | 0.250 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2006 | 194 | 0.240 |
Why?
|
| Mutagenesis | 1 | 2005 | 131 | 0.240 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 832 | 0.240 |
Why?
|
| Enzyme Inhibitors | 3 | 2015 | 346 | 0.240 |
Why?
|
| Lysosomes | 6 | 2010 | 163 | 0.230 |
Why?
|
| Gene Expression | 5 | 2007 | 807 | 0.230 |
Why?
|
| Membrane Glycoproteins | 4 | 2007 | 669 | 0.230 |
Why?
|
| Flow Cytometry | 8 | 2016 | 639 | 0.230 |
Why?
|
| Egg Proteins | 4 | 2007 | 23 | 0.230 |
Why?
|
| Gene Deletion | 2 | 2021 | 298 | 0.230 |
Why?
|
| Jurkat Cells | 2 | 2019 | 102 | 0.230 |
Why?
|
| Substrate Specificity | 7 | 2011 | 325 | 0.230 |
Why?
|
| Mutation | 8 | 2021 | 2471 | 0.220 |
Why?
|
| Poliovirus | 2 | 2000 | 5 | 0.220 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2002 | 139 | 0.220 |
Why?
|
| Histocompatibility Antigens | 2 | 2023 | 107 | 0.220 |
Why?
|
| Biological Factors | 1 | 2003 | 23 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 419 | 0.220 |
Why?
|
| Protein Transport | 2 | 2019 | 398 | 0.210 |
Why?
|
| Transcription, Genetic | 3 | 2021 | 848 | 0.210 |
Why?
|
| Cell Adhesion | 2 | 1995 | 209 | 0.210 |
Why?
|
| Male | 20 | 2024 | 27971 | 0.210 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2008 | 75 | 0.210 |
Why?
|
| Tetraspanins | 1 | 2022 | 13 | 0.210 |
Why?
|
| Glycosylphosphatidylinositols | 4 | 1999 | 24 | 0.200 |
Why?
|
| Immune Evasion | 1 | 2023 | 54 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2005 | 577 | 0.200 |
Why?
|
| Kidney Neoplasms | 3 | 2008 | 114 | 0.200 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 1996 | 58 | 0.200 |
Why?
|
| Ligands | 5 | 2013 | 422 | 0.190 |
Why?
|
| COS Cells | 3 | 2009 | 175 | 0.190 |
Why?
|
| Cell Adhesion Molecules | 3 | 1991 | 88 | 0.190 |
Why?
|
| Endocytosis | 2 | 2000 | 148 | 0.190 |
Why?
|
| Cluster Analysis | 1 | 2022 | 252 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 1999 | 304 | 0.190 |
Why?
|
| Glycolipids | 2 | 1992 | 45 | 0.190 |
Why?
|
| Female | 25 | 2016 | 31250 | 0.190 |
Why?
|
| In Vitro Techniques | 10 | 1999 | 472 | 0.190 |
Why?
|
| Molecular Chaperones | 2 | 2016 | 99 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 35 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 603 | 0.180 |
Why?
|
| Transplantation Chimera | 1 | 2000 | 38 | 0.180 |
Why?
|
| Bone Transplantation | 1 | 2000 | 28 | 0.180 |
Why?
|
| Chemokines | 2 | 2013 | 94 | 0.180 |
Why?
|
| Ubiquitin | 3 | 2009 | 95 | 0.180 |
Why?
|
| Hydrolysis | 5 | 2006 | 139 | 0.170 |
Why?
|
| Sepsis | 1 | 2024 | 282 | 0.170 |
Why?
|
| Cell Movement | 4 | 2012 | 425 | 0.170 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 144 | 0.170 |
Why?
|
| Kinetics | 9 | 2011 | 738 | 0.170 |
Why?
|
| Interleukin-2 | 6 | 1996 | 164 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 215 | 0.170 |
Why?
|
| Molecular Weight | 6 | 2003 | 189 | 0.170 |
Why?
|
| Lymphoma, T-Cell | 3 | 1999 | 21 | 0.160 |
Why?
|
| Prostatic Neoplasms | 3 | 2011 | 330 | 0.160 |
Why?
|
| Racemases and Epimerases | 3 | 2004 | 24 | 0.160 |
Why?
|
| Fetus | 1 | 1999 | 97 | 0.160 |
Why?
|
| Cell Line, Transformed | 3 | 2010 | 97 | 0.160 |
Why?
|
| Mice, Inbred AKR | 5 | 2005 | 12 | 0.160 |
Why?
|
| Lipopolysaccharides | 3 | 2024 | 645 | 0.160 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2019 | 196 | 0.150 |
Why?
|
| B7-1 Antigen | 1 | 1998 | 73 | 0.150 |
Why?
|
| Carcinoma, Papillary | 2 | 2008 | 37 | 0.150 |
Why?
|
| Cloning, Molecular | 2 | 2012 | 385 | 0.150 |
Why?
|
| 3T3 Cells | 3 | 2003 | 108 | 0.150 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2010 | 178 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2011 | 146 | 0.150 |
Why?
|
| Nucleoproteins | 2 | 1999 | 31 | 0.150 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2012 | 218 | 0.150 |
Why?
|
| Phenotype | 5 | 2015 | 1158 | 0.150 |
Why?
|
| Viral Core Proteins | 2 | 1999 | 30 | 0.140 |
Why?
|
| T-Lymphocyte Subsets | 4 | 1998 | 237 | 0.140 |
Why?
|
| Adenocarcinoma | 4 | 2009 | 327 | 0.140 |
Why?
|
| Acetylcysteine | 1 | 1997 | 24 | 0.140 |
Why?
|
| Lactones | 1 | 1997 | 25 | 0.140 |
Why?
|
| Microspheres | 4 | 1998 | 55 | 0.140 |
Why?
|
| Rabbits | 4 | 2006 | 331 | 0.140 |
Why?
|
| Vaccines | 1 | 1998 | 97 | 0.140 |
Why?
|
| Phospholipases | 2 | 1987 | 9 | 0.140 |
Why?
|
| Cytoplasm | 4 | 2002 | 274 | 0.130 |
Why?
|
| Ascitic Fluid | 2 | 2012 | 12 | 0.130 |
Why?
|
| Protozoan Vaccines | 1 | 2016 | 13 | 0.130 |
Why?
|
| Clone Cells | 6 | 1997 | 106 | 0.130 |
Why?
|
| Viruses | 2 | 2008 | 79 | 0.130 |
Why?
|
| Chagas Disease | 1 | 2016 | 34 | 0.130 |
Why?
|
| Cell Proliferation | 4 | 2011 | 943 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 807 | 0.130 |
Why?
|
| Leucine | 3 | 2011 | 61 | 0.130 |
Why?
|
| Crystallization | 2 | 2012 | 97 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2012 | 558 | 0.120 |
Why?
|
| History, 20th Century | 2 | 2007 | 230 | 0.120 |
Why?
|
| Febuxostat | 1 | 2014 | 2 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 5 | 1999 | 275 | 0.120 |
Why?
|
| Xanthine Oxidase | 1 | 2014 | 11 | 0.120 |
Why?
|
| Immunity, Cellular | 3 | 1996 | 176 | 0.120 |
Why?
|
| Gout Suppressants | 1 | 2014 | 25 | 0.120 |
Why?
|
| Immunity, Innate | 2 | 2011 | 768 | 0.120 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2014 | 9 | 0.120 |
Why?
|
| Survival Rate | 3 | 2012 | 793 | 0.120 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 2 | 1991 | 14 | 0.120 |
Why?
|
| RNA, Messenger | 7 | 2009 | 1470 | 0.120 |
Why?
|
| Base Sequence | 4 | 2005 | 1313 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 78 | 0.110 |
Why?
|
| Zymosan | 1 | 2013 | 23 | 0.110 |
Why?
|
| Acetaminophen | 1 | 2014 | 52 | 0.110 |
Why?
|
| Tetracycline | 1 | 2013 | 20 | 0.110 |
Why?
|
| Recombinant Proteins | 5 | 2010 | 697 | 0.110 |
Why?
|
| Catalysis | 2 | 2012 | 152 | 0.110 |
Why?
|
| Models, Biological | 4 | 2012 | 1143 | 0.110 |
Why?
|
| Protein Stability | 1 | 2013 | 85 | 0.110 |
Why?
|
| Lymphocyte Cooperation | 8 | 1992 | 30 | 0.110 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1993 | 24 | 0.110 |
Why?
|
| Morpholines | 1 | 2013 | 85 | 0.110 |
Why?
|
| Prostate | 2 | 2011 | 54 | 0.110 |
Why?
|
| Thy-1 Antigens | 5 | 1992 | 21 | 0.110 |
Why?
|
| Chloroquine | 4 | 1997 | 49 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 1994 | 131 | 0.110 |
Why?
|
| Neoplasm Metastasis | 3 | 2008 | 196 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2010 | 155 | 0.100 |
Why?
|
| Inteins | 1 | 2012 | 3 | 0.100 |
Why?
|
| Hot Temperature | 2 | 1998 | 127 | 0.100 |
Why?
|
| Tetradecanoylphorbol Acetate | 4 | 1999 | 65 | 0.100 |
Why?
|
| Vaccination | 1 | 1995 | 344 | 0.100 |
Why?
|
| Mice, Mutant Strains | 2 | 2008 | 304 | 0.100 |
Why?
|
| Peptide Chain Elongation, Translational | 1 | 2012 | 11 | 0.100 |
Why?
|
| Intestines | 1 | 2013 | 156 | 0.100 |
Why?
|
| Cell Separation | 5 | 1997 | 147 | 0.100 |
Why?
|
| Electrons | 1 | 2012 | 34 | 0.100 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 2087 | 0.100 |
Why?
|
| Carcinoma | 2 | 2004 | 117 | 0.100 |
Why?
|
| Mast Cells | 1 | 2012 | 41 | 0.100 |
Why?
|
| Monocytes | 3 | 2012 | 345 | 0.100 |
Why?
|
| Polymers | 9 | 1992 | 317 | 0.100 |
Why?
|
| Solubility | 3 | 2002 | 176 | 0.100 |
Why?
|
| Binding, Competitive | 4 | 2001 | 100 | 0.100 |
Why?
|
| Ireland | 1 | 2012 | 17 | 0.100 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2012 | 75 | 0.100 |
Why?
|
| Venereal Tumors, Veterinary | 1 | 2011 | 1 | 0.100 |
Why?
|
| Tomography, Optical | 1 | 2011 | 3 | 0.100 |
Why?
|
| Mice, Inbred DBA | 5 | 2000 | 84 | 0.100 |
Why?
|
| Ribosomes | 1 | 2014 | 154 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 31 | 0.100 |
Why?
|
| Cell Aggregation | 3 | 1999 | 21 | 0.100 |
Why?
|
| Cytochalasin B | 3 | 1997 | 23 | 0.100 |
Why?
|
| Chickens | 3 | 2000 | 91 | 0.090 |
Why?
|
| Intracellular Space | 1 | 2011 | 33 | 0.090 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 29 | 0.090 |
Why?
|
| Genes, ras | 1 | 1991 | 28 | 0.090 |
Why?
|
| Thymus Neoplasms | 1 | 1991 | 21 | 0.090 |
Why?
|
| Pleural Neoplasms | 1 | 2011 | 17 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2011 | 26 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 23 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 737 | 0.090 |
Why?
|
| Epithelium | 1 | 2011 | 97 | 0.090 |
Why?
|
| Meningeal Neoplasms | 1 | 2011 | 57 | 0.090 |
Why?
|
| Meningioma | 1 | 2011 | 58 | 0.090 |
Why?
|
| Cold Temperature | 1 | 1991 | 51 | 0.090 |
Why?
|
| Cell Division | 3 | 2002 | 443 | 0.090 |
Why?
|
| Vesicular stomatitis Indiana virus | 2 | 2005 | 16 | 0.090 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 1992 | 144 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 354 | 0.090 |
Why?
|
| Amines | 1 | 1991 | 30 | 0.090 |
Why?
|
| Lymphokines | 3 | 1990 | 66 | 0.090 |
Why?
|
| Macromolecular Substances | 4 | 1996 | 160 | 0.090 |
Why?
|
| Protein Folding | 1 | 2012 | 261 | 0.090 |
Why?
|
| Hypoxia | 1 | 2011 | 109 | 0.090 |
Why?
|
| Cystinyl Aminopeptidase | 1 | 2010 | 2 | 0.090 |
Why?
|
| Protein Conformation | 5 | 2002 | 774 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 449 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 94 | 0.090 |
Why?
|
| Subcellular Fractions | 2 | 2004 | 66 | 0.090 |
Why?
|
| Cytokines | 1 | 1994 | 911 | 0.090 |
Why?
|
| Pregnancy Proteins | 1 | 2010 | 17 | 0.090 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2010 | 1 | 0.090 |
Why?
|
| CD11b Antigen | 1 | 2010 | 21 | 0.090 |
Why?
|
| Radiation Chimera | 1 | 2010 | 57 | 0.090 |
Why?
|
| Type C Phospholipases | 2 | 1987 | 33 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2006 | 855 | 0.090 |
Why?
|
| Adenovirus E3 Proteins | 1 | 2009 | 2 | 0.080 |
Why?
|
| Poly I-C | 1 | 2009 | 76 | 0.080 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2009 | 53 | 0.080 |
Why?
|
| Influenza A virus | 1 | 1991 | 117 | 0.080 |
Why?
|
| Multigene Family | 1 | 1989 | 93 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 239 | 0.080 |
Why?
|
| Middle Aged | 9 | 2016 | 16535 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 1991 | 1539 | 0.080 |
Why?
|
| Barrett Esophagus | 1 | 2009 | 33 | 0.080 |
Why?
|
| Comorbidity | 1 | 2012 | 1098 | 0.080 |
Why?
|
| Structure-Activity Relationship | 4 | 2011 | 376 | 0.080 |
Why?
|
| Genetic Vectors | 2 | 2009 | 820 | 0.080 |
Why?
|
| Cysteine Proteinase Inhibitors | 3 | 1999 | 21 | 0.080 |
Why?
|
| Mice, SCID | 2 | 2011 | 509 | 0.080 |
Why?
|
| Cholesterol | 1 | 2010 | 255 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2003 | 130 | 0.080 |
Why?
|
| Silicosis | 1 | 2008 | 4 | 0.080 |
Why?
|
| Atherosclerosis | 1 | 2010 | 148 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 72 | 0.080 |
Why?
|
| Young Adult | 3 | 2016 | 4396 | 0.080 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2008 | 16 | 0.080 |
Why?
|
| Crosses, Genetic | 2 | 2000 | 105 | 0.080 |
Why?
|
| Autophagy | 1 | 2010 | 208 | 0.070 |
Why?
|
| Binding Sites | 3 | 2011 | 873 | 0.070 |
Why?
|
| CD8 Antigens | 3 | 1994 | 54 | 0.070 |
Why?
|
| Cerulenin | 1 | 1987 | 1 | 0.070 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 3 | 1995 | 5 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 80 | 0.070 |
Why?
|
| Phosphoric Diester Hydrolases | 3 | 1995 | 17 | 0.070 |
Why?
|
| Immunity | 1 | 2009 | 97 | 0.070 |
Why?
|
| Interferon Type I | 1 | 2009 | 168 | 0.070 |
Why?
|
| Azides | 3 | 1993 | 19 | 0.070 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 233 | 0.070 |
Why?
|
| Cricetulus | 2 | 1999 | 102 | 0.070 |
Why?
|
| Isoantigens | 2 | 1985 | 72 | 0.070 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 12 | 0.070 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2007 | 17 | 0.070 |
Why?
|
| Prevalence | 1 | 2012 | 1300 | 0.070 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2007 | 10 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 62 | 0.070 |
Why?
|
| Biomarkers | 1 | 2012 | 1213 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2005 | 185 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2008 | 854 | 0.070 |
Why?
|
| Phospholipases A | 1 | 1987 | 11 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 1987 | 117 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 2007 | 55 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2008 | 112 | 0.070 |
Why?
|
| Peroxidase | 1 | 2007 | 70 | 0.070 |
Why?
|
| Receptors, Transferrin | 2 | 2000 | 35 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 53 | 0.070 |
Why?
|
| Nucleocapsid Proteins | 2 | 1999 | 34 | 0.070 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2006 | 11 | 0.070 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 33 | 0.070 |
Why?
|
| Urate Oxidase | 1 | 2006 | 1 | 0.070 |
Why?
|
| Viral Envelope Proteins | 1 | 2007 | 111 | 0.070 |
Why?
|
| Brefeldin A | 2 | 1997 | 8 | 0.070 |
Why?
|
| Cyclopentanes | 2 | 1997 | 8 | 0.070 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 151 | 0.070 |
Why?
|
| Precipitin Tests | 2 | 1999 | 79 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 661 | 0.060 |
Why?
|
| Methylation | 2 | 1996 | 127 | 0.060 |
Why?
|
| Protein Binding | 3 | 1999 | 1566 | 0.060 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2005 | 11 | 0.060 |
Why?
|
| Adult | 6 | 2016 | 15985 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 248 | 0.060 |
Why?
|
| Glycoproteins | 1 | 1986 | 194 | 0.060 |
Why?
|
| Leupeptins | 3 | 1994 | 16 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2005 | 100 | 0.060 |
Why?
|
| Binding Sites, Antibody | 2 | 2001 | 29 | 0.060 |
Why?
|
| Cross-Linking Reagents | 3 | 1992 | 113 | 0.060 |
Why?
|
| Quality Control | 1 | 2005 | 70 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 1986 | 293 | 0.060 |
Why?
|
| Uteroglobin | 1 | 2004 | 7 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2004 | 27 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2000 | 502 | 0.060 |
Why?
|
| Pleural Effusion | 1 | 2004 | 34 | 0.060 |
Why?
|
| Particle Size | 2 | 1997 | 403 | 0.060 |
Why?
|
| Immunoglobulin Constant Regions | 1 | 2004 | 8 | 0.060 |
Why?
|
| Mice, Inbred C3H | 3 | 1995 | 175 | 0.060 |
Why?
|
| DNA Virus Infections | 1 | 2004 | 9 | 0.060 |
Why?
|
| Amino Acids | 2 | 2002 | 139 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2004 | 80 | 0.060 |
Why?
|
| Autoimmunity | 1 | 2006 | 221 | 0.060 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 2 | 1995 | 2 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 1985 | 171 | 0.060 |
Why?
|
| Tuberculosis | 2 | 1998 | 268 | 0.050 |
Why?
|
| Temperature | 2 | 1996 | 299 | 0.050 |
Why?
|
| Phosphoinositide Phospholipase C | 2 | 1995 | 32 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2011 | 460 | 0.050 |
Why?
|
| Protein Biosynthesis | 3 | 1996 | 296 | 0.050 |
Why?
|
| Drosophila | 2 | 2010 | 420 | 0.050 |
Why?
|
| Plant Proteins | 2 | 1995 | 83 | 0.050 |
Why?
|
| Intracellular Fluid | 2 | 2010 | 32 | 0.050 |
Why?
|
| Antigens, Differentiation | 3 | 1998 | 141 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 309 | 0.050 |
Why?
|
| Enzyme Induction | 3 | 1998 | 44 | 0.050 |
Why?
|
| Aged | 4 | 2012 | 13581 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2009 | 104 | 0.050 |
Why?
|
| CD4 Antigens | 2 | 1994 | 156 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 455 | 0.050 |
Why?
|
| Prognosis | 3 | 2011 | 1591 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 327 | 0.050 |
Why?
|
| Psoriasis | 1 | 2002 | 51 | 0.050 |
Why?
|
| Colon | 1 | 2003 | 139 | 0.050 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2001 | 17 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2012 | 5262 | 0.050 |
Why?
|
| DNA | 3 | 1991 | 793 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 910 | 0.050 |
Why?
|
| Diffusion | 1 | 2001 | 84 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2002 | 215 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2009 | 196 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 1991 | 53 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 215 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2000 | 36 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 391 | 0.040 |
Why?
|
| Immunosorbent Techniques | 2 | 1991 | 10 | 0.040 |
Why?
|
| Ammonium Chloride | 2 | 1991 | 10 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 233 | 0.040 |
Why?
|
| Chimera | 1 | 1999 | 42 | 0.040 |
Why?
|
| HLA-D Antigens | 1 | 1999 | 20 | 0.040 |
Why?
|
| B7-2 Antigen | 1 | 1998 | 32 | 0.040 |
Why?
|
| Immune Sera | 1 | 1998 | 35 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 1999 | 82 | 0.040 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 1998 | 2 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 1998 | 71 | 0.040 |
Why?
|
| Calcimycin | 2 | 1988 | 19 | 0.040 |
Why?
|
| Biotechnology | 1 | 1998 | 42 | 0.040 |
Why?
|
| Point Mutation | 1 | 1999 | 164 | 0.040 |
Why?
|
| Viral Vaccines | 1 | 1998 | 49 | 0.040 |
Why?
|
| Antibody Formation | 2 | 1992 | 112 | 0.040 |
Why?
|
| Vaccines, DNA | 1 | 1998 | 99 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2002 | 1137 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 1998 | 90 | 0.040 |
Why?
|
| Species Specificity | 2 | 1991 | 335 | 0.040 |
Why?
|
| Guinea Pigs | 1 | 1997 | 103 | 0.040 |
Why?
|
| Viral Proteins | 1 | 1999 | 261 | 0.040 |
Why?
|
| RNA Interference | 2 | 2011 | 592 | 0.040 |
Why?
|
| beta-Lactams | 1 | 1997 | 11 | 0.040 |
Why?
|
| Chemistry | 2 | 1988 | 30 | 0.040 |
Why?
|
| Chemical Phenomena | 2 | 1988 | 93 | 0.040 |
Why?
|
| Parainfluenza Virus 1, Human | 2 | 1994 | 2 | 0.030 |
Why?
|
| Time Factors | 3 | 2011 | 3618 | 0.030 |
Why?
|
| Microinjections | 1 | 1996 | 66 | 0.030 |
Why?
|
| Protein Denaturation | 1 | 1996 | 66 | 0.030 |
Why?
|
| Stem Cells | 1 | 1998 | 258 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 1132 | 0.030 |
Why?
|
| Trypanosoma cruzi | 1 | 2016 | 49 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 193 | 0.030 |
Why?
|
| Disease Progression | 2 | 2011 | 1054 | 0.030 |
Why?
|
| Up-Regulation | 2 | 1998 | 365 | 0.030 |
Why?
|
| Trinitrobenzenes | 3 | 1984 | 7 | 0.030 |
Why?
|
| Massachusetts | 2 | 2011 | 2118 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 1995 | 81 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 47 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 665 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 1998 | 312 | 0.030 |
Why?
|
| Half-Life | 1 | 1995 | 70 | 0.030 |
Why?
|
| Cathepsin L | 2 | 2010 | 20 | 0.030 |
Why?
|
| Iron | 1 | 1995 | 144 | 0.030 |
Why?
|
| Rats | 2 | 2012 | 1918 | 0.030 |
Why?
|
| Oncogenes | 1 | 1994 | 69 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 1994 | 119 | 0.030 |
Why?
|
| Stromal Cells | 1 | 1994 | 65 | 0.030 |
Why?
|
| Mast-Cell Sarcoma | 1 | 1993 | 1 | 0.030 |
Why?
|
| Pinocytosis | 1 | 1993 | 4 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 1993 | 31 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 525 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1993 | 34 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1993 | 49 | 0.030 |
Why?
|
| Cyanogen Bromide | 1 | 1992 | 2 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 1998 | 647 | 0.030 |
Why?
|
| Ricin | 1 | 1992 | 3 | 0.020 |
Why?
|
| Ethylmaleimide | 1 | 1992 | 8 | 0.020 |
Why?
|
| Formaldehyde | 1 | 1992 | 32 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1996 | 389 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1992 | 21 | 0.020 |
Why?
|
| Receptor Aggregation | 1 | 1991 | 5 | 0.020 |
Why?
|
| Metallothionein | 1 | 1991 | 8 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2011 | 38 | 0.020 |
Why?
|
| Pleura | 1 | 2011 | 12 | 0.020 |
Why?
|
| Blood | 1 | 1991 | 27 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 148 | 0.020 |
Why?
|
| CD3 Complex | 1 | 1991 | 64 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1995 | 630 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1991 | 56 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 183 | 0.020 |
Why?
|
| Methylamines | 1 | 1991 | 6 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2011 | 85 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1991 | 113 | 0.020 |
Why?
|
| California | 1 | 2011 | 162 | 0.020 |
Why?
|
| Ataxin-3 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Interferons | 1 | 1991 | 63 | 0.020 |
Why?
|
| Mice, Nude | 1 | 1991 | 260 | 0.020 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1990 | 3 | 0.020 |
Why?
|
| Lymphoma | 1 | 1991 | 100 | 0.020 |
Why?
|
| Diet, Atherogenic | 1 | 2010 | 7 | 0.020 |
Why?
|
| alpha-Synuclein | 1 | 2010 | 22 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2010 | 31 | 0.020 |
Why?
|
| Dogs | 1 | 2011 | 307 | 0.020 |
Why?
|
| Exons | 1 | 1991 | 193 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2010 | 33 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 516 | 0.020 |
Why?
|
| Phagocytes | 1 | 2010 | 49 | 0.020 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2010 | 63 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2010 | 136 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2010 | 74 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 109 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 136 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 193 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 423 | 0.020 |
Why?
|
| Huntingtin Protein | 1 | 2010 | 138 | 0.020 |
Why?
|
| Genetic Linkage | 2 | 1988 | 101 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2001 | 197 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 148 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 302 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2011 | 460 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2009 | 9 | 0.020 |
Why?
|
| Trypsin | 1 | 1989 | 42 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2009 | 20 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 458 | 0.020 |
Why?
|
| Esophagus | 1 | 2009 | 52 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 214 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2010 | 196 | 0.020 |
Why?
|
| Aluminum Compounds | 1 | 2008 | 10 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1991 | 661 | 0.020 |
Why?
|
| Immunoblotting | 2 | 2001 | 190 | 0.020 |
Why?
|
| Lectins | 1 | 1988 | 38 | 0.020 |
Why?
|
| Poly A | 1 | 1988 | 27 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2010 | 336 | 0.020 |
Why?
|
| Membrane Lipids | 1 | 1988 | 27 | 0.020 |
Why?
|
| Monensin | 1 | 1987 | 4 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 1987 | 11 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1988 | 111 | 0.020 |
Why?
|
| Urothelium | 1 | 2008 | 22 | 0.020 |
Why?
|
| Silicon Dioxide | 1 | 2008 | 59 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 104 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 417 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 5197 | 0.020 |
Why?
|
| Mice, Inbred A | 2 | 1984 | 20 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 1987 | 12 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 36 | 0.020 |
Why?
|
| Pronase | 1 | 1986 | 3 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1987 | 71 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1986 | 33 | 0.020 |
Why?
|
| Cervix Uteri | 1 | 2006 | 57 | 0.020 |
Why?
|
| Glycosylation | 1 | 1986 | 135 | 0.020 |
Why?
|
| Thymoma | 1 | 1986 | 11 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1988 | 367 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 1002 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1986 | 12 | 0.020 |
Why?
|
| Concanavalin A | 2 | 1982 | 40 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 760 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 299 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 5958 | 0.020 |
Why?
|
| Mammaglobin A | 1 | 2004 | 2 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1986 | 175 | 0.020 |
Why?
|
| Polyglutamic Acid | 1 | 1984 | 11 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 639 | 0.010 |
Why?
|
| Cell Fusion | 1 | 1984 | 45 | 0.010 |
Why?
|
| Polylysine | 1 | 1984 | 49 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 1983 | 201 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1984 | 194 | 0.010 |
Why?
|
| Calcium | 1 | 1987 | 558 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 1035 | 0.010 |
Why?
|
| Alleles | 1 | 1984 | 424 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 2002 | 18 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1983 | 124 | 0.010 |
Why?
|
| Nitrobenzenes | 1 | 1982 | 2 | 0.010 |
Why?
|
| Adenoma | 1 | 2003 | 64 | 0.010 |
Why?
|
| Insulin | 1 | 1986 | 689 | 0.010 |
Why?
|
| Keratins | 1 | 2001 | 31 | 0.010 |
Why?
|
| DNA Replication | 1 | 1984 | 229 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 288 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1100 | 0.010 |
Why?
|
| Puromycin | 1 | 2001 | 4 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2001 | 25 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1983 | 224 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 2362 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 598 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1066 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 1998 | 11 | 0.010 |
Why?
|
| CD24 Antigen | 1 | 1998 | 17 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1998 | 55 | 0.010 |
Why?
|
| Hyaluronan Receptors | 1 | 1998 | 35 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1998 | 112 | 0.010 |
Why?
|
| Mycobacterium | 1 | 1998 | 36 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 157 | 0.010 |
Why?
|
| Listeria monocytogenes | 1 | 1996 | 33 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 1998 | 212 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1994 | 26 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2006 | 6139 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1996 | 688 | 0.010 |
Why?
|
| p-Azobenzenearsonate | 1 | 1982 | 1 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1982 | 56 | 0.000 |
Why?
|
| Hybridization, Genetic | 1 | 1978 | 14 | 0.000 |
Why?
|